{ "id": "ep45ncydrn", "slug": "carboplatin-and-gemcitabine-regimen", "title": "Carboplatin and gemcitabine regimen", "updated": "2026-09-30", "topic_path": [ { "id": "life", "label": "Life and health", "api_url": "https://www.edgepedia.org/api/v1/topics/life" }, { "id": "life.health", "label": "Human health and medicine", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health" }, { "id": "life.health.medicines", "label": "Medicines and therapeutics", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.medicines" }, { "id": "life.health.medicines.cancer-chemotherapy", "label": "Cancer chemotherapy and regimens", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.medicines.cancer-chemotherapy" }, { "id": "life.health.medicines.cancer-chemotherapy.platinum-based-regimens", "label": "Platinum-based regimens", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.medicines.cancer-chemotherapy.platinum-based-regimens" } ], "geo": [ { "id": "geo.nongeo.t1946.life.health.medicines.cancer-chemotherapy", "label": "Non-geographic · 1946 to 2000: Cancer chemotherapy and regimens", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health.medicines.cancer-chemotherapy", "path": [ { "id": "geo.nongeo", "label": "Non-geographic", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo" }, { "id": "geo.nongeo.t1946", "label": "Non-geographic · 1946 to 2000", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946" }, { "id": "geo.nongeo.t1946.life", "label": "Life and health", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life" }, { "id": "geo.nongeo.t1946.life.health", "label": "Human health and medicine", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health" }, { "id": "geo.nongeo.t1946.life.health.medicines", "label": "Medicines and therapeutics", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health.medicines" }, { "id": "geo.nongeo.t1946.life.health.medicines.cancer-chemotherapy", "label": "Cancer chemotherapy and regimens", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health.medicines.cancer-chemotherapy" } ] } ], "excerpt": "The carboplatin and gemcitabine regimen, or Carboplatin-Gemcitabine, is a doublet chemotherapy pairing carboplatin with gemcitabine, standard for recurrent ovarian cancer and advanced non-small-cell lung cancer.", "snippet": "The carboplatin and gemcitabine regimen, or Carboplatin-Gemcitabine, is a doublet chemotherapy pairing carboplatin with gemcitabine, standard for recurrent ovarian cancer and advanced non-small-cell lung cancer.", "node": "life.health.medicines.cancer-chemotherapy.platinum-based-regimens", "markdown": "# Carboplatin and gemcitabine regimen\n\nThe carboplatin and gemcitabine regimen is a doublet chemotherapy combination that pairs the platinum drug carboplatin, dosed by area under the concentration-time curve (AUC), with the antimetabolite gemcitabine, given most often as gemcitabine 1000 mg/m² on days 1 and 8 plus carboplatin AUC 5 on day 1 of a 21-day cycle.[1](https://assets.hse.ie/media/documents/310_GemCARBOAUC_5.pdf) It is a standard option for platinum-sensitive recurrent ovarian cancer,[2](https://www.cancercareontario.ca/en/drugformulary/regimens/monograph/45321) advanced non-small-cell lung cancer (NSCLC), locally advanced or metastatic biliary tract cancer (where it is combined with durvalumab),[3](https://www.cancercareontario.ca/en/drugformulary/regimens/monograph/75751) and cisplatin-ineligible urothelial carcinoma, including with added nivolumab.[4](https://aacrjournals.org/clincancerres/article/32/14/2911/786634/Gemcitabine-plus-Nivolumab-with-Carboplatin-or) Because carboplatin avoids the nephrotoxicity, neurotoxicity, and ototoxicity of cisplatin at standard doses, the doublet is often chosen for patients with moderate renal impairment.[5](https://www.sciencedirect.com/science/article/abs/pii/S0302283806015892)\n\n| Key fact | Value |\n|---|---|\n| Standard schedule | Gemcitabine 1000 mg/m² IV days 1 and 8; carboplatin AUC 5 IV day 1; repeat every 21 days for 4–6 cycles[1](https://assets.hse.ie/media/documents/310_GemCARBOAUC_5.pdf) |\n| Carboplatin dose calculation | Dose (mg) = \\( \\text{target AUC} \\times (\\text{GFR} + 25) \\), the Calvert formula[1](https://assets.hse.ie/media/documents/310_GemCARBOAUC_5.pdf) |\n| Platinum-sensitive recurrent ovarian cancer | Median PFS 8.6 vs 5.8 months versus carboplatin alone (HR 0.72); overall survival not significantly improved[6](https://ascopubs.org/doi/10.1200/JCO.2006.06.0913) |\n| Advanced NSCLC (vs MIC) | Median survival 10 vs 7.6 months (HR 0.76); 1-year survival 40% vs 30%[7](https://pubmed.ncbi.nlm.nih.gov/15625369/) |\n| Biliary tract cancer (UK cohort) | Median OS 8.97 months, PFS 5.88 months; grade 3–4 hematologic toxicity in 51.5%[8](https://www.mdpi.com/2072-6694/17/19/3102) |\n| Urothelial + nivolumab (GU16-287) | ORR 69.6% with gemcitabine/carboplatin/nivolumab vs 33.3% with the oxaliplatin arm[4](https://aacrjournals.org/clincancerres/article/32/14/2911/786634/Gemcitabine-plus-Nivolumab-with-Carboplatin-or) |\n| Dose-limiting toxicity | Myelosuppression, especially thrombocytopenia[5](https://www.sciencedirect.com/science/article/abs/pii/S0302283806015892) |\n\n## How it works\n\nCarboplatin forms predominantly intrastrand DNA cross-links, with interstrand cross-links a smaller proportion (3-4%), that block replication and transcription.[18](https://doi.org/10.1016/j.jab.2015.03.003) [Gemcitabine](https://www.edgepedia.org/gemcitabine), a deoxycytidine analog, inhibits the repair of these cross-links: in patients' lymphocytes, peak carboplatin-induced cross-linking occurs by 24 hours, and administration of gemcitabine after carboplatin produces a significant reduction in cross-link repair, a pharmacodynamic demonstration of synergy for the doublet.[9](https://aacrjournals.org/clincancerres/article/16/19/4899/75651/Inhibition-of-Carboplatin-Induced-DNA-Interstrand)\n\nCarboplatin was chosen over cisplatin for tolerability. The dose-limiting toxicity of carboplatin is myelosuppression, especially thrombocytopenia, whereas standard doses of carboplatin (up to 400 mg/m²) do not cause the nephrotoxicity, neurotoxicity, or ototoxicity seen with cisplatin.[5](https://www.sciencedirect.com/science/article/abs/pii/S0302283806015892) In the carboplatin arm of the GU16-287 trial, plasma IFNγ and the T-cell homing chemokines [CXCL9](https://www.edgepedia.org/cxcl9) and CXCL10 rose consistently after treatment started, an adaptive immune activation that may contribute when the doublet is paired with checkpoint inhibitors.[4](https://aacrjournals.org/clincancerres/article/32/14/2911/786634/Gemcitabine-plus-Nivolumab-with-Carboplatin-or)\n\n## How it is done\n\nThe reference protocol gives gemcitabine 1000 mg/m² IV over 30 minutes on days 1 and 8 and carboplatin AUC 5 IV over 30 minutes on day 1, every 21 days, for 4 to 6 cycles or until progression or unacceptable toxicity.[1](https://assets.hse.ie/media/documents/310_GemCARBOAUC_5.pdf) [Carboplatin](https://www.edgepedia.org/carboplatin) is dosed with the Calvert formula, Dose (mg) = target AUC (mg/mL × min) × (GFR mL/min + 25).[1](https://assets.hse.ie/media/documents/310_GemCARBOAUC_5.pdf) Because the Cockcroft-Gault formula underestimates GFR by about 10%, an AUC of 6 rather than 5 was recommended in trials when GFR was estimated that way.[7](https://pubmed.ncbi.nlm.nih.gov/15625369/) Patients with creatinine clearance below 60 mL/min are at greater risk of myelosuppression; carboplatin is given with extreme caution at GFR 20 to 30 mL/min and not at all at GFR ≤20 mL/min.[1](https://assets.hse.ie/media/documents/310_GemCARBOAUC_5.pdf)\n\nDay-8 gemcitabine is modified by the day-8 blood counts: full dose if ANC above 1 × 10⁹/L and platelets above 100 × 10⁹/L, 75% if ANC 0.5–1 × 10⁹/L or platelets 50–100 × 10⁹/L, and omitted if ANC below 0.5 × 10⁹/L or platelets below 50 × 10⁹/L.[1](https://assets.hse.ie/media/documents/310_GemCARBOAUC_5.pdf) In a platinum-resistant ovarian protocol, gemcitabine was reduced to 800 mg/m² for delays over one week, neutropenic fever, or grade 4 thrombocytopenia.[9](https://aacrjournals.org/clincancerres/article/16/19/4899/75651/Inhibition-of-Carboplatin-Induced-DNA-Interstrand) Monitoring includes a CBC before each cycle and on day 8, plus baseline and regular renal function tests and electrolytes (including magnesium) and liver function tests.[2](https://www.cancercareontario.ca/en/drugformulary/regimens/monograph/45321) In biliary tract cancer, baseline CA 19-9 above 2000 U/mL and alkaline phosphatase above 180 IU/L identify patients with significantly worse survival.[8](https://www.mdpi.com/2072-6694/17/19/3102)\n\n## Origin\n\nThe doublet entered practice through phase I work: an early phase I trial was planned specifically to define the maximum tolerated dose and dose-limiting toxicity of carboplatin-gemcitabine, its authors noting that existing data on the combination were insufficient to plan phase II trials.[10](https://pubmed.ncbi.nlm.nih.gov/11828946/) The AUC dosing the regimen depends on was established by A. H. Calvert and colleagues in 1989 in the *Journal of Clinical Oncology*, a prospective evaluation of a dosing formula based on renal function.[11](https://doi.org/10.1200/jco.1989.7.11.1748) In biliary tract cancer, the doublet was evaluated in a phase II single-institution study by Kerry J. Williams and colleagues, published in *HPB* in 2010.[12](https://doi.org/10.1111/j.1477-2574.2010.00197.x) The cisplatin-gemcitabine standard that carboplatin regimens in that disease are positioned against was established by [Juan Valle](https://www.edgepedia.org/juan-w-valle) and colleagues in the ABC-02 trial, published in the *New England Journal of Medicine* in 2010.[13](https://doi.org/10.1056/nejmoa0908721)\n\n## Variants\n\n**Doublet plus immunotherapy.** In the HCRN GU16-287 randomized phase II trial (NCT03451331, 49 cisplatin-ineligible patients with metastatic urothelial carcinoma), gemcitabine 1000 mg/m², carboplatin AUC 4.5, and nivolumab 360 mg achieved an objective response rate of 69.6% versus 33.3% for gemcitabine plus oxaliplatin plus nivolumab; median OS was 24.74 versus 16.43 months (HR 1.99; P=0.07).[4](https://aacrjournals.org/clincancerres/article/32/14/2911/786634/Gemcitabine-plus-Nivolumab-with-Carboplatin-or) Patients with at least stable disease after six cycles could continue maintenance single-agent nivolumab 480 mg for up to 12 cycles.[14](https://clinicaltrials.gov/study/NCT03451331)\n\n**Biliary tract cancer with durvalumab.** Cancer Care Ontario funds carboplatin AUC 5 day 1, gemcitabine 1000 mg/m² days 1 and 8, and durvalumab 1500 mg day 1 every 21 days for up to 8 cycles, followed by durvalumab maintenance, as first-line palliative therapy for locally advanced unresectable or metastatic biliary tract cancer, supported by a February 2023 CADTH reimbursement recommendation.[3](https://www.cancercareontario.ca/en/drugformulary/regimens/monograph/75751)\n\n**Neoadjuvant NSCLC.** Since May 2024, Ireland's HSE protocol also covers the doublet with nivolumab for neoadjuvant treatment of resectable NSCLC with PD-L1 expression ≥1%, limited to 3 cycles.[1](https://assets.hse.ie/media/documents/310_GemCARBOAUC_5.pdf)\n\n## Applications\n\n**Platinum-sensitive recurrent ovarian cancer.** In the 356-patient intergroup phase III trial (AGO-OVAR, NCIC CTG, EORTC GCG), gemcitabine plus carboplatin extended median PFS to 8.6 versus 5.8 months (HR 0.72; P=.0031) and raised the response rate from 30.9% to 47.2% (P=.0016), without worsening quality of life.[6](https://ascopubs.org/doi/10.1200/JCO.2006.06.0913) The trial used gemcitabine 1000 mg/m² days 1 and 8 with carboplatin AUC 4 in the combination arm versus single-agent carboplatin AUC 5.[15](https://www.eviq.org.au/getmedia/efe21e81-e67a-4998-8c5a-8dba39768e72/ID-1680-Ovarian-recurrent-cARBOplatin-and-gemcitabine-day-1-cARBOplatin-protocol-and-PI.pdf.aspx)\n\n**Advanced NSCLC.** In the London Lung Cancer Group trial, 422 patients randomized to gemcitabine 1200 mg/m² days 1 and 8 plus carboplatin AUC 5 versus mitomycin, ifosfamide, and cisplatin (MIC) had median survival of 10 versus 7.6 months (HR 0.76; P=.008) and 1-year survival of 40% versus 30%.[7](https://pubmed.ncbi.nlm.nih.gov/15625369/) In the three-arm British Thoracic Oncology Group trial (1363 patients), carboplatin AUC 6 plus gemcitabine 1250 mg/m² was non-inferior to cisplatin 80 mg/m² for survival (HR 0.93; median 10.0 vs 9.5 months).[16](https://pmc.ncbi.nlm.nih.gov/articles/PMC5597318/)\n\n**Biliary tract cancer.** In a UK cohort of 66 patients treated with carboplatin AUC 2.5 on days 1 and 8 plus gemcitabine 1000 mg/m² days 1 and 8, median OS was 8.97 months, PFS 5.88 months, and tumor control 70%.[8](https://www.mdpi.com/2072-6694/17/19/3102) The benchmark is ABC-02, where cisplatin plus gemcitabine gave median OS of 11.7 versus 8.1 months with gemcitabine alone (HR 0.64).[17](https://www.nejm.org/doi/full/10.1056/NEJMoa0908721)\n\n**Urothelial carcinoma.** A randomized phase 2 trial found gemcitabine-carboplatin on a 21-day schedule active and comparably tolerable to gemcitabine-cisplatin in locally advanced or metastatic transitional cell carcinoma, and proposed it as an alternative especially for patients with moderate renal failure.[5](https://www.sciencedirect.com/science/article/abs/pii/S0302283806015892)\n\n## Limitations and alternatives\n\n**Thrombocytopenia shapes the schedule.** An initial phase I study established the combination on a 4-week schedule with gemcitabine on days 1, 8, and 15, but a subsequent phase II trial showed unacceptable thrombocytopenia on that schedule, motivating adoption of the 3-week schedule with carboplatin AUC 5 on day 1 and gemcitabine on days 1 and 8.[7](https://pubmed.ncbi.nlm.nih.gov/15625369/) Even on the 3-week schedule, treatment delays occurred in 24% of cycles, largely from myelosuppression, and 15% of day-8 gemcitabine doses were omitted.[9](https://aacrjournals.org/clincancerres/article/16/19/4899/75651/Inhibition-of-Carboplatin-Induced-DNA-Interstrand)\n\n**Efficacy limits.** In the ovarian trial, progression-free survival and response improved but overall survival did not (HR 0.96; P=.7349).[6](https://ascopubs.org/doi/10.1200/JCO.2006.06.0913) In the BTOG2 NSCLC trial, the carboplatin arm had more grade 3–4 adverse events, more dose reductions and delays, and no quality-of-life advantage.[16](https://pmc.ncbi.nlm.nih.gov/articles/PMC5597318/) Unlike cisplatin, standard doses of carboplatin avoid nephrotoxicity, neurotoxicity, and ototoxicity, while the dose-limiting toxicity is myelosuppression, especially thrombocytopenia.[5](https://www.sciencedirect.com/science/article/abs/pii/S0302283806015892)\n\n**Alternatives and open comparisons.** In metastatic urothelial carcinoma, the EV-302 trial established enfortumab vedotin plus pembrolizumab as a standard regardless of cisplatin eligibility, though platinum chemotherapy remains relevant for accessibility, cost, and salvage use.[4](https://aacrjournals.org/clincancerres/article/32/14/2911/786634/Gemcitabine-plus-Nivolumab-with-Carboplatin-or)\n\n## References\n\n1. [NCCP Regimen 00310 Gemcitabine (1000mg/m2) and CARBOplatin (AUC 5) Therapy - 21 day](https://assets.hse.ie/media/documents/310_GemCARBOAUC_5.pdf)\n2. [Cancer Care Ontario regimen monograph: carboplatin and gemcitabine (platinum-sensitive recurrent ovarian cancer)](https://www.cancercareontario.ca/en/drugformulary/regimens/monograph/45321)\n3. [Cancer Care Ontario Drug Formulary: CRBPGEMC+DURV Regimen (Carboplatin-Gemcitabine-Durvalumab)](https://www.cancercareontario.ca/en/drugformulary/regimens/monograph/75751)\n4. [Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial (HCRN GU16-287)](https://aacrjournals.org/clincancerres/article/32/14/2911/786634/Gemcitabine-plus-Nivolumab-with-Carboplatin-or)\n5. [Gemcitabine plus Cisplatin versus Gemcitabine plus Carboplatin as First-Line Chemotherapy in Advanced Transitional Cell Carcinoma of the Urothelium: Results of a Randomized Phase 2 Trial](https://www.sciencedirect.com/science/article/abs/pii/S0302283806015892)\n6. [Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG](https://ascopubs.org/doi/10.1200/JCO.2006.06.0913)\n7. [Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in stage IIIB/IV NSCLC: phase III randomized study of the London Lung Cancer Group](https://pubmed.ncbi.nlm.nih.gov/15625369/)\n8. [Efficacy and Toxicity Profile of Carboplatin/Gemcitabine Chemotherapy in Locally Advanced or Metastatic Biliary Tract Cancer: A Single UK Centre Experience](https://www.mdpi.com/2072-6694/17/19/3102)\n9. [Inhibition of Carboplatin-Induced DNA Interstrand Cross-link Repair by Gemcitabine in Patients Receiving these Drugs for Platinum-Resistant Ovarian Cancer](https://aacrjournals.org/clincancerres/article/16/19/4899/75651/Inhibition-of-Carboplatin-Induced-DNA-Interstrand)\n10. [Combination chemotherapy of carboplatin and gemcitabine against solid tumors: a phase I trial](https://pubmed.ncbi.nlm.nih.gov/11828946/)\n11. [A H Calvert and colleagues (1989). Carboplatin dosage: prospective evaluation of a simple formula based on renal function.. Journal of Clinical Oncology.](https://doi.org/10.1200/jco.1989.7.11.1748)\n12. [Kerry J. Williams and colleagues (2010). Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study. HPB.](https://doi.org/10.1111/j.1477-2574.2010.00197.x)\n13. [Juan Valle and colleagues (2010). Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. New England Journal of Medicine.](https://doi.org/10.1056/nejmoa0908721)\n14. [NCT03451331: Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Metastatic Urothelial Cancer](https://clinicaltrials.gov/study/NCT03451331)\n15. [eviQ 1680: Ovarian recurrent carboplatin and gemcitabine (day 1 carboplatin) protocol](https://www.eviq.org.au/getmedia/efe21e81-e67a-4998-8c5a-8dba39768e72/ID-1680-Ovarian-recurrent-cARBOplatin-and-gemcitabine-day-1-cARBOplatin-protocol-and-PI.pdf.aspx)\n16. [Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial](https://pmc.ncbi.nlm.nih.gov/articles/PMC5597318/)\n17. [Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer (ABC-02)](https://www.nejm.org/doi/full/10.1056/NEJMoa0908721)\n18. [Zx3mdhtcwyj (exa.ai)](https://doi.org/10.1016/j.jab.2015.03.003)\n\n---\n*Topic: Encyclopedia › Life and health › Human health and medicine › Medicines and therapeutics › Cancer chemotherapy and regimens › Platinum-based regimens*\n\n*Initially written Sep 29, 2026 · Reviewed: Sep 30, 2026 · Edited: Sep 30, 2026 · Last review: Sep 30, 2026*\n\n*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*\n\nLicense: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license\n", "same_as": [], "url": "https://www.edgepedia.org/carboplatin-and-gemcitabine-regimen", "markdown_url": "https://www.edgepedia.org/carboplatin-and-gemcitabine-regimen.md", "license": { "name": "Edgepedia Community License 1.0", "url": "https://www.edgepedia.org/edgepedia/license", "summary": "Free with credit, commercial use included. AI training is open to everyone. For other uses, organizations over USD 100M in revenue or 100M monthly users license separately.", "spdx": "LicenseRef-Edgepedia-Community-1.0" }, "credit": "\"Carboplatin and gemcitabine regimen\", Edgepedia (EdgeChat), https://www.edgepedia.org/carboplatin-and-gemcitabine-regimen. Edgepedia Community License 1.0.", "credit_md": "\"[Carboplatin and gemcitabine regimen](https://www.edgepedia.org/carboplatin-and-gemcitabine-regimen)\", Edgepedia (EdgeChat), [https://www.edgepedia.org/carboplatin-and-gemcitabine-regimen](https://www.edgepedia.org/carboplatin-and-gemcitabine-regimen). [Edgepedia Community License 1.0](https://www.edgepedia.org/edgepedia/license).", "credit_html": "\"Carboplatin and gemcitabine regimen\", Edgepedia (EdgeChat), https://www.edgepedia.org/carboplatin-and-gemcitabine-regimen. Edgepedia Community License 1.0.", "speakable": "The carboplatin and gemcitabine regimen, or Carboplatin-Gemcitabine, is a doublet chemotherapy pairing carboplatin with gemcitabine, standard for recurrent ovarian cancer and advanced non-small-cell lung cancer." }